These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 29860286)

  • 21. Towards elimination of lymphatic filariasis: social mobilization issues and challenges in mass drug administration with anti-filarial drugs in Tamil Nadu, South India.
    Nandha B; Krishnamoorthy K; Jambulingam P
    Health Educ Res; 2013 Aug; 28(4):591-8. PubMed ID: 23503571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modelling lymphatic filariasis elimination in American Samoa: GEOFIL predicts need for new targets and six rounds of mass drug administration.
    McLure A; Graves PM; Lau C; Shaw C; Glass K
    Epidemics; 2022 Sep; 40():100591. PubMed ID: 35816826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ongoing transmission of lymphatic filariasis in Samoa 4.5 years after one round of triple-drug mass drug administration.
    Mayfield HJ; Sartorius B; Sheridan S; Howlett M; Martin BM; Thomsen R; Tofaeono-Pifeleti R; Viali S; Graves PM; Lau CL
    PLoS Negl Trop Dis; 2024 Jun; 18(6):e0012236. PubMed ID: 38935622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A community survey of coverage and adverse events following country-wide triple-drug mass drug administration for lymphatic filariasis elimination, Samoa 2018.
    Willis GA; Mayfield HJ; Kearns T; Naseri T; Thomsen R; Gass K; Sheridan S; Graves PM; Lau CL
    PLoS Negl Trop Dis; 2020 Nov; 14(11):e0008854. PubMed ID: 33253148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endpoints for lymphatic filariasis programs.
    Grady CA; de Rochars MB; Direny AN; Orelus JN; Wendt J; Radday J; Mathieu E; Roberts JM; Streit TG; Addiss DG; Lammie PJ
    Emerg Infect Dis; 2007 Apr; 13(4):608-10. PubMed ID: 17553278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of microfilaremia in 'hotspots' of four lymphatic filariasis endemic districts of Nepal during post-MDA surveillance.
    Mehta PK; Maharjan M
    PLoS Negl Trop Dis; 2024 Jan; 18(1):e0011932. PubMed ID: 38295107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of six rounds of single dose mass treatment with diethylcarbamazine or ivermectin on Wuchereria bancrofti infection and its implications for lymphatic filariasis elimination.
    Ramaiah KD; Vanamail P; Pani SP; Yuvaraj J; Das PK
    Trop Med Int Health; 2002 Sep; 7(9):767-74. PubMed ID: 12225508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis.
    Krentel A; Basker N; Beau de Rochars M; Bogus J; Dilliott D; Direny AN; Dubray C; Fischer PU; Ga AL; Goss CW; Hardy M; Howard C; Jambulingam P; King CL; Laman M; Lemoine JF; Mallya S; Robinson LJ; Samuela J; Schechtman KB; Steer AC; Supali T; Tavul L; Weil GJ
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009002. PubMed ID: 33657090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes.
    Ramaiah KD; Das PK; Vanamail P; Pani SP
    Trop Med Int Health; 2003 Dec; 8(12):1082-92. PubMed ID: 14641843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Individual Efficacy and Community Impact of Ivermectin, Diethylcarbamazine, and Albendazole Mass Drug Administration for Lymphatic Filariasis Control in Fiji: A Cluster Randomized Trial.
    Hardy M; Samuela J; Kama M; Tuicakau M; Romani L; Whitfeld MJ; King CL; Weil GJ; Grobler AC; Robinson LJ; Kaldor JM; Steer AC
    Clin Infect Dis; 2021 Sep; 73(6):994-1002. PubMed ID: 33728462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surveillance and Selective Treatment of Brugia malayi Filariasis Eleven Years after Stopping Mass Drug Administration in Belitung District, Indonesia.
    Supali T; Djuardi Y; ; Sianipar LR; Suryaningtyas NH; Alfian R; Destani Y; Iskandar E; Astuty H; Sugianto N; Fischer PU
    Am J Trop Med Hyg; 2024 Jan; 110(1):111-116. PubMed ID: 38011734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti.
    de Kraker ME; Stolk WA; van Oortmarssen GJ; Habbema JD
    Trop Med Int Health; 2006 May; 11(5):718-28. PubMed ID: 16640625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Towards elimination of lymphatic filariasis in southeastern Madagascar: Successes and challenges for interrupting transmission.
    Garchitorena A; Raza-Fanomezanjanahary EM; Mioramalala SA; Chesnais CB; Ratsimbasoa CA; Ramarosata H; Bonds MH; Rabenantoandro H
    PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006780. PubMed ID: 30222758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First evidence of lymphatic filariasis transmission interruption in Cameroon: Progress towards elimination.
    Nana-Djeunga HC; Tchouakui M; Njitchouang GR; Tchatchueng-Mbougua JB; Nwane P; Domche A; Bopda J; Mbickmen-Tchana S; Akame J; Tarini A; Epée E; Biholong BD; Zhang Y; Tougoue JJ; Kabore A; Njiokou F; Kamgno J
    PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005633. PubMed ID: 28662054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
    Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
    Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress on elimination of lymphatic filariasis in Sierra Leone.
    Koroma JB; Sesay S; Conteh A; Paye J; Bah M; Sonnie M; Hodges MH; Zhang Y
    Parasit Vectors; 2018 Jun; 11(1):334. PubMed ID: 29866207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transmission indices and microfilariae prevalence in human population prior to mass drug administration with ivermectin and albendazole in the Gomoa District of Ghana.
    Aboagye-Antwi F; Kwansa-Bentum B; Dadzie SK; Ahorlu CK; Appawu MA; Gyapong J; Wilson MD; Boakye DA
    Parasit Vectors; 2015 Oct; 8():562. PubMed ID: 26503363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of mass drug administration for elimination of lymphatic filariasis in Nepal.
    Ojha CR; Joshi B; Kc KP; Dumre SP; Yogi KK; Bhatta B; Adhikari T; Crowley K; Marasini BR
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005788. PubMed ID: 28723904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decline in lymphatic filariasis transmission with annual mass drug administration using DEC with and without albendazole over a 10year period in India.
    Sunish IP; Kalimuthu M; Rajendran R; Munirathinam A; Ashok Kumar V; Nagaraj J; Tyagi BK
    Parasitol Int; 2015 Feb; 64(1):1-4. PubMed ID: 25205435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire.
    Edi C; Bjerum CM; Ouattara AF; Chhonker YS; Penali LK; Méité A; Koudou BG; Weil GJ; King CL; Murry DJ
    PLoS Negl Trop Dis; 2019 May; 13(5):e0007325. PubMed ID: 31107869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.